Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses

Young-Tae Lee¹, Eun-Ju Ko¹, Youri Lee¹, Ki-Hye Kim¹, Min-Chul Kim¹-², Yu-Na Lee¹-², Sang-Moo Kang¹*

¹ Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States of America, ² Animal and Plant Quarantine Agency, Gimcheon, Gyeongsangbukdo, Republic of Korea

Abstract

Current influenza vaccines do not provide broad cross-protection. Here, we report that intranasal vaccination with virus-like particles containing the highly conserved multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus induces broad cross-protection by M2-specific humoral and cellular immune responses. M2e5x VLP intranasal vaccination prevented severe weight loss, attenuated inflammatory cytokines and cellular infiltrates, and lowered viral loads, and induced germinal center phenotypic B and plasma cells. In addition, depletion studies demonstrate the protective roles of CD4 and CD8 T cells induced by M2e5x VLP intranasal vaccination. Thus, this study provides evidence that mucosal delivery of M2e5x VLP vaccine provides cross-protection by inducing humoral and cellular immune responses.

Introduction

Influenza virus causes respiratory viral diseases in humans and animals, with significant medical and economic burdens. Approximately 250,000–500,000 deaths are estimated annually worldwide due to influenza-related disease [1, 2]. The emergence of the 2009 pandemic H1N1 virus is an example of a new strain with distinct antigenic properties by triple reassortment [3, 4]. While antibodies to hemagglutinin (HA) provide strain-specific protection, the current vaccine formulations are not effective in protection against antigenically distinct strains.

The ion-channel protein M2 has an extracellular domain of 24 amino acids (M2e) which is a conserved molecular target among human influenza A strains [5, 6]. To overcome the low immunogenicity of M2 protein, previous studies approached M2e-conjugate carrier vehicles, potent adjuvants, and multiple immunizations with high vaccine doses [7–14]. In a previous study, we generated a molecular construct containing a tandem repeat of M2 ectodomain and
presented it on virus-like particles (M2e5x VLP) [15]. Intramuscular immunization with M2e5x VLP in the absence of adjuvants induced M2 specific antibodies and cross-protection [15].

Since influenza virus is a respiratory pathogen, mucosal immunization with cross protective M2e-based vaccines could be effective in conferring protection. Previous studies reported that intranasal immunization with M2e-conjugate protein vaccines with chitosan adjuvant or M2e-flagellin adjuvant chimeric on VLP resulted in survival protection despite severe weight loss [16–18]. Nasal-inactivated vaccines in clinical trials raised serum and mucosal antibodies which could be cross-protective and have the advantages of potential application to the high risk groups over live vaccines [19]. In this study, we investigated the immunogenicity and efficacy of M2e5x VLP intranasal immunization in a mouse model. Also, to better understand cross protective immune correlates after intranasal vaccination, detail systemic and local cellular immune responses including germinal center and plasma cells, and cytokine-secreting T cell responses were determined, demonstrating the effective cross protection preventing weight loss.

Materials and methods

Viruses and M2e5x VLP vaccines

Mouse adapted A/Philippines/2/1982 (A/Phil, H3N2) virus was generously provided by Dr. Huan Nguyen. Reassortant A/Viet rgH5N1 virus (rgH5N1; HA and NA were derived from A/Vietnam/1203/2004 and the backbone genes from A/PR/8/34 virus) was previously described [20]. The reassortant rgH5N1 virus has the same M2e from the M gene of A/PR8. Viruses were propagated in embryonated chicken eggs, and allantoic fluids clarified by centrifugation (3600 × g, 30 minutes [min]) and kept at -80˚C. M2e5x VLP (Fig 1A) was produced using the recombinant baculovirus (rBV) expression system as previously described [15]. Briefly, to produce M2e5x VLPs, Sf9 cells were coinfected with rBVs expressing influenza M1 matrix protein and a tandem repeat of M2 ectodomains (M2e5x) derived from human (2x, SLLTEVETPIRNEWGSRSN), swine (1x, SLLTEVETPTRSEWESRSS), Avian 1 (1x, SLLTEVETPTREWESRSS), and Avian 2 (1x, SLLTEVETLRNGWGCRCS) influenza viruses (Fig 1A). Culture supernatants containing M2e5x VLP were collected by centrifugation at 2,000 × g for 20 min and further spun by ultra-centrifugation at 100,000 × g for 1 hour (h). M2e5x VLP was further purified by ultracentrifugation using discontinuous sucrose gradients (20%-30%-60%). A recommended level for recombinant subunit vaccines is 20 endotoxin units (EU)/ml [21]. The endotoxin levels of prepared 5xM2e VLP vaccine were determined by Chromogenic LAL endotoxin assay kit (Cat# L00350, GenScript) and found to be less than 1.2 EU/15 μg 5xM2e VLP, which is within an acceptable level.

Immunization and challenge

Female BALB/c mice (n = 5 per group, 6- to 8-week-old) purchased from Harlan Laboratories were intranasally immunized with 15 μg of M2e5x VLP total proteins (0.9 μg M2e5x proteins) in 50 μl at weeks 0 and 4. Immune sera were collected to determine antigen-specific antibody responses 3 weeks after prime and boost immunizations. M2e5x VLP immune mice were challenged with a lethal dose (5×LD₅₀) of A/Phil (H3N2) or A/Viet (rgH5N1) virus at 6 weeks after boost immunization. In separate experiments, mice were sacrificed to collect samples at day 0 (before challenge), or day 3 and 6 post infection (Fig 2A). If mice show weight loss above the endpoint (20%) compared to the control animals, then mice are euthanized immediately. The mice that show clinical signs of illness such as ruffled hair coat and/or difficult breathing are humanely euthanized to avoid the pain. The methods of euthanasia used in the study include
isoflurane and carbon dioxide, and death is confirmed by cervical dislocation. Animals are anesthetized using isoflurane inhalation before the distressful procedures to relieve the pain. All animal experiments were approved and performed under the guidelines by the Georgia State University Institutional Animal Care and Use protocol (A14025).

**Humoral immune responses**

The levels of M2e specific antibody titers were determined by ELISA using human type M2e peptides (SLLTEVETPIRNEWGSRSN) as a coating antigen. ELISA 96-well plates were coated with M2e peptides (4 μg/ml) overnight and then blocked with 1% bovine serum albumin (BSA) and 0.05% Tween 20 in phosphate-buffered saline (PBS) for 1.5 h at 37°C. After wash, diluted samples (sera, bronchoalveolar lavage fluid [BALF], or in vitro culture supernatants) were added and incubated for 1.5 h at 37°C. For determination of class-switched antibodies, the horse radish peroxidase (HRP)-conjugated goat anti-mouse IgG, IgG1, IgG2a, and IgA secondary antibodies (Southern Biotechnology) were used. The substrate of 3,3′,5,5′-tetramethylbenzidine (TMB) (Sigma Aldrich) was used to develop color and stopped with 1M H₃PO₄. The OD value was determined at 450nm using a BioTek ELISA plate reader. Antibody amounts were quantified using the standard curve for each IgG isotype antibody.
Fig 2. M2e5x VLP intranasal immunization induces mucosal antibodies and cross-protection preventing weight loss. (A) A detailed timeline for the vaccination, challenge, and sampling strategy. BALB/c mice that were intranasally immunized with M2e5x VLPs (15 μg/mouse) at weeks 0 and 4, and were challenged with different subtype influenza viruses at week 10. Day 3, 6, and 14 indicate the days when samples were analyzed or body weight changes monitored for 14 days during virus infection. (B) Body weight change and (C) survival rates after challenge with A/Phil (H3N2) (5 × LD₅₀). (D) Body weight changes after challenge with A/Viet/rgH5N1. (E) Lung viral loads (log₁₀ EID₅₀/ml). (F) IgG to M2 peptide in BAL. (G) IgA to M2 peptide in BAL.
T cell depletion experiments

To understand the role of CD4 T and CD8 T cells in protection, M2e5x VLP immune mice were intravenously injected with anti-CD4 (200 μg in 200 μl, Clone GK1.5, Catalog # BE003-1) and anti-CD8 (150 μg in 200 μl, Catalog # BE0061) depletion antibodies (Bio X Cell) at 2 days before infection and 1 day after infection with A/Phil (H3N2) virus. The levels of T cell depletion were confirmed by flow cytometry, resulting in depleting T cells over 99% (S1 Fig). Injection of IgG isotype control (Clone LTF-2, rat IgG2b, Cat # BE0090, BioXCell) did not affect the depletion of T cells similar to PBS. Body weight changes were monitored for 7 days. Lung viral loads were determined by measuring embryonated egg infectious unit titers at 7 days after challenge.

Determination of antibody producing cells

To determine the levels of in vitro M2e specific antibody production as a measure of antibody secreting cells, the splenocytes (memory B cells) and bone marrow (plasma) cells were collected at day 6 post challenge. Million cells isolated from spleens and bone marrow were added in triplicates (10⁶ cells / 0.2 ml) to M2e peptide-coated plates and then incubated for 1 or 5 days at 37°C. The IgG antibodies secreted into supernatants after in vitro cultures for 1 or 5 days were determined by ELISA as described above.

Cytokine assays

To compare inflammatory responses, proinflammatory cytokines were measured by cytokine ELISAs, performed as previously described by Lee et al. [22]. Briefly, Ready-Set-Go interferon-gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) kits (eBioscience, San Diego, CA) were used to determine the amounts of cytokines in the BALF and lung extracts following the manufacturer’s procedures.

Cell preparation and intracellular cytokine staining analysis

Immune cells were harvested from the airways via BAL. The lung tissues were homogenized and lung extracts spun on 44/67% Percoll at 3600 × g, for 15 min. The layer containing cells between 44 and 67% Percoll gradients were collected for the analysis of lung cells. The mediastinal lymph nodes (MLNs) were grinded using the frosted glass microscope slides to make cell suspensions. For antigen-specific T cell responses, the cells from the BAL and lungs were in vitro stimulated with human M2 peptides (5 μg / ml) for 5 h at 37°C in the presence of Brefeldin A (BFA) (20μg/ml). After stimulation, lymphocytes were stained with CD4 (CD4-PE/Cy5, Cat# 100410, Biolegend) and CD8 (CD8α-PE, Cat# 100708, Biolegend) monoclonal antibodies. BD Cytofix/Cytoperm™ Plus kit was used to fix and permeabilize specific marker labelled lymphocytes and cytokine positive cells were then stained with IFN-γ cytokine antibodies (anti-mouse IFN-γ APC-Cy7, Cat# 561479, BD biosciences). All samples were analyzed on a Becton-Dickinson LSR-II/Fortessa flow cytometer (BD biosciences, San Diego, CA) and analyzed by using Flowjo software (Tree Star Inc.).
Lung viral titers
To determine lung viral loads, 10-fold serial dilutions (200 μl) of the lung homogenates were injected in the 10-day-old embryonated chicken eggs and incubated for 2 days. The allantoic fluids harvested after 2 days incubation were incubated with chicken red blood cells in 96-well V-bottom plates to determine hemagglutination activity as an indicator for virus replication. Lung viral titers were calculated by the Reed-Muench method [23].

Statistics
Statistical significance was determined by using an unpaired two-tailed Student’s t test or one-way ANOVA. Results represent the means ± SEM (standard error of mean). Statistical analyses were performed using Prism software (* P <0.05, ** P <0.01, *** P <0.001).

Results
M2e5x VLP intranasal vaccination induces cross-reactive M2e- antibodies
Mucosal delivery of M2e5x VLP vaccine is expected to be effective in inducing protection against influenza virus respiratory pathogens. BALB/c mice (n = 10) were intranasally immunized with M2e5x VLP (15 μg) in a prime-boost strategy with a 4-week interval. Levels of antibodies specific for M2 peptides were low after prime, but boost immunization significantly increased M2 specific antibodies in sera (Fig 1B). M2e5x VLP vaccination resulted in similar amounts of IgG2a and IgG1 antibodies (Fig 1C), suggesting Th2 and Th1 immune responses. M2e5x VLP immune sera displayed low levels of cross reactivity to different heterosubtypic viruses A/California/2009 (A/Cal H1N1), A/Philippines/2/82 (A/Phil H3N2), and reassortant A/Vietnam/1203/2004 (A/Viet rgH5N1) (data not shown).

Intranasal delivery of M2e5x VLP confers effective cross protection
Next, we assessed cross protective efficacy of M2e5x VLP intranasal vaccination. M2e5x VLP vaccinated mice were challenged with A/Philippines/2/1982 (A/Phil) (H3N2) or A/Viet rgH5N1 virus at 6 weeks after boost (Fig 2A). After A/Phil (H3N2) virus challenge, naïve mice showed a significant loss (approximately 25%) in body weight and died at day 8 or 9 (Fig 2B and 2C). In contrast, mice vaccinated with M2e5x VLP displayed 10% weight loss during 5 to 6 days and rapidly recovered body weight to a normal level by day 9 (Fig 2B). Infection of naïve mice with rgH5N1 resulted in over 17% loss in body weight, whereas M2e5x VLP immunized mice showed significantly less weight loss (2–3%) and fully recovered by day 6 after challenge (Fig 2D).

M2e5x VLP-immunized mice revealed a 14-fold decrease in virus titers compared to naïve mice with infection at 3 days after challenge (Fig 2E). Day 6 post challenge, lung viral loads in M2e5x VLP immune mice displayed approximately 76-fold lower than those in naïve mice. We also determined whether M2e5x VLP immunization induced M2-specific mucosal antibodies. Higher levels of M2-specific IgG and IgA antibodies were observed in the BAL fluids of immune mice than those in naïve mice before or after rgH5N1 virus challenge (Fig 2F and 2G). These results suggest that intranasal vaccination with M2e5x VLP induces M2-specific antibodies in sera and mucosal tissues, conferring effective cross-protection against heterosubtypic influenza viruses.
M2e5x VLP intranasal vaccination prevents lung inflammatory responses after challenge

Since over-production of cytokines causes severe pulmonary inflammatory responses during highly pathogenic influenza virus infection [24, 25], we determined the levels of IFN-γ and TNF-α. Naive mice were observed to secrete IFN-γ at day 3 and showed a dramatic increase in the levels of IFN-γ in the BAL and lungs day 6 post-infection (Fig 3A and 3B). In contrast, IFN-γ was not detected at day 3 and lower amounts of IFN-γ were observed in the BAL and lungs of M2e5x VLP immune mice day 6 post-infection (Fig 3A and 3B). In addition, the levels of TNF-α in the BAL and lungs from naïve mice were higher than those in immune mice day 3 and 6 post infection (Fig 3C and 3D). These data indicate that intranasal vaccination with M2e5x VLP effectively attenuates lung inflammatory cytokines after infection.

M2e5x VLP vaccination reduces innate immune cell recruitment upon virus infection

To better understand inflammatory cellular infiltration, we determined monocytes (CD11b^Ly6ch^F4/80^+) and neutrophils (CD11b^Ly6c^-F4/80^-) in the lungs upon influenza virus infection. At 6 days after infection, significantly higher numbers of inflammatory monocytes were detected in the BAL and lungs from naïve mice than those from M2e5x VLP immunized mice. (Fig 4A). In addition, a large number of infiltrating neutrophils from unimmune mice were observed in the lungs but not in the BAL compared to those in immune mice.
M2e5x VLP vaccination attenuates inflammatory innate cell infiltration into the lungs upon virus infection at 6 days after infection.

**M2e5x VLP vaccination enhances germinal center (GC) B cells and antibody-secreting cell responses**

We determined whether M2e5x VLP intranasal immunization would enhance B cell activation and M2e-specific antibody producing cell responses. GL7+ GC B cells (CD19+ B220+) [26] were analyzed in the mediastinal lymph nodes (MLN) after challenge with rgH5N1. High numbers of GL7+ GC phenotypic B cells were observed in the MLN of immune mice compared to those in naïve mice day 3 and 6 post-infection (Fig 5A). To determine M2e-specific antibody secreting cell responses, the cells from the spleens and bone marrow were collected and cultured in the presence of M2e peptides. Significantly higher amounts of M2e specific
antibodies were secreted from the splenocytes and bone marrow cells of M2e5x VLP immune mice compared to those in naïve mice during 1 to 5 days of cultures containing M2e peptides (Fig 5B and 5C). These data on GL7⁺ B cells and significant levels of in vitro antibody secreting cells suggest that M2e5x VLP intranasal vaccination is effective in inducing GC B cells and plasma cells.

**M2e5x VLP vaccination induces protective T cell responses**

To determine M2e-specific T cell responses, the cells harvested from the BAL fluids and lungs before and after influenza virus infection were stimulated with M2e peptides. Cytokine-producing cellular responses were analyzed by an intracellular cytokine staining assay. TNF-α or IFN-γ producing CD4⁺ T cells were detected at higher levels in the BAL and lungs from the M2e5x VLP immune mice than those in naïve mice before challenge (day 0) and day 3 post-challenge (Fig 6). TNF-α or IFN-γ producing CD4⁺ T cells in the lungs of immune mice were increased in numbers (TNF-α: 2.4-fold; IFN-γ: 2.4-fold) day 6 post-challenge (Fig 6B and 6D). These results suggest that a low level of effector M2-specific T cells appears at the lung parenchymal tissues, which may be rapidly expanding upon virus infection.

We further investigated the roles of CD4⁺ and CD8⁺ T cells in conferring protection. M2e5x VLP-vaccinated mice were administered PBS, CD4, or CD8 depletion antibodies...
before and during challenge with A/Phil (H3N2) virus (Fig 7). PBS-treated M2e5x VLP immune mice showed a better recovery in body weight than CD4- or CD8-depleted immune mice at 6 and 7 days after challenge (Fig 7A). Meanwhile, a substantial weight loss was observed in naïve mice day 6 and 7 post infection (approximately 15 and 20%, respectively). In line with body weight loss, highest levels of lung virus titers were detected in naïve mice but M2e5x VLP immune mice that received with PBS showed lowest lung viral loads 7 days after infection (Fig 7B). As a result of CD4 depletion antibody treatment, lung viral loads significantly increased in immune mice compared to PBS-treated immune mice. Interestingly, CD8-depleted immune mice showed higher lung virus titers than CD4-depleted immune mice but lower than naïve mice, suggesting a role of CD8 T cells in protection by clearing lung viral loads in M2e5x VLP vaccinated mice (Fig 7B). These data suggest that intranasal vaccination with M2e5x VLPs induces cross protective T cell responses.

Discussion

Cross protective cellular immune responses remain not well understood yet after mucosal vaccination. Here, we investigated the protective and immunological effects of intranasal vaccination with M2e5x VLPs. This study shows that intranasal vaccination with M2e5x VLP induces M2e-specific humoral and cellular immune responses including GC B cells, and plasma cells secreting M2e-specific antibodies as well as local CD4 and CD8 T cells likely contributing to cross protection. Therefore, intranasal vaccination with M2e5x VLP has the capacity to induce humoral and cellular immunity locally and systemically, which effectively confer cross protection against different serotypes of influenza viruses.
Many M2e-based vaccine studies were reported and evaluated in mice after systemic vaccination. Intranasal immunization was shown to be effective in inducing cross protection in mice [27, 28]. M2e protein (M2e5x) vaccines are a poor immunogen in the absence of adjuvants (data not shown). Various amounts of M2e vaccine doses (10 μg–60 μg) in combination with different conjugate carriers and potent adjuvants were used to vaccinate mice [18, 29–33]. Nonetheless, M2e vaccines were not highly effective and M2e-vaccinated mice showed significant weight loss after challenge [7–14, 18, 29–33]. There are few studies on intranasal immunization with M2e vaccines (20–100 μg) in the presence of adjuvants [17, 18]. Protective efficacy of M2e vaccines was low and detailed cellular immune responses remain unknown.

Our previous study reported that intramuscular immunization with M2e5x VLPs in the absence of adjuvants induced M2 specific antibodies capable of conferring cross-protection [15]. Intramuscular prime immunization (10 μg of M2e5x VLP) induced significant levels of M2e antibodies as reported in our previous study [15]. In the current study, low levels of M2e antibodies were induced after intranasal prime immunization, which were significantly increased by boost vaccination (Fig 1B). It is also unclear how M2e5x VLP IM immune sera showed substantial levels of cross reactive antibodies to different viruses [15] whereas the intranasal immune sera displayed low levels of cross reactive antibodies (data not shown). Nonetheless, the levels of M2e specific antibodies after intranasal prime-boost vaccination (15 μg of M2e5x VLP) were found to be similar to those after IM prime-boost immunization (data not shown). It is expected that intranasal immune sera would exhibit in vivo protective effects since Intramuscular prime boost sera were shown to induce in vivo protection [15].

This study has focused on immune responses of B and T cells as well as on preventing inflammatory disease after intranasal immunization with M2e5x VLP and heterosubtypic influenza virus challenges. We found that intranasal immunization with M2e5x VLP was effective in inducing M2e specific IgG antibodies in sera systemically as well as IgG and IgA in BALF locally. Also, intranasal immunization with M2e5x VLP resulted in rapid expansion of GC GL7+ B cells in the draining MLN after challenge (day 0 to 6, Fig 5A), major sites of antigen drainage from the respiratory tracts [34]. In line with B cell expansion, an approximately 10-fold increase in M2e-specific IgG antibody levels during the 5 days of in vitro cultures suggest the induction of memory B cells that are rapidly differentiating into plasma cells secreting antibodies.

There seems to be a correlation between systemic disease of weight loss and levels of inflammatory cytokines (TNF-α, INF-γ) and cellular infiltrates (monocytes, neutrophils). This study suggests that intranasal immunization with M2e5x VLP induces effective cross protection. When C57BL/6 mice were intramuscularly vaccinated with M2e5x VLP in the presence of adjuvant (Alum+monophosphoryl lipid A [MPL]) and challenged, lower levels of interleukin (IL)-6 were detected in the vaccinated group than those in unvaccinated mice [35]. In the current study, BALB/c mice were intranasally vaccinated with M2e5x VLP without using any adjuvant. Pathogenic influenza virus infection causes severe lung inflammation characterized as proinflammatory cytokine storm and cellular infiltrates, which might lead to systemic disease of multi-organ failure [36, 37]. In response to inflammatory cytokines and chemokines, innate inflammatory cells such as neutrophils and monocytes as well as dendritic cells are recruited to the sites of viral infection, further contributing to the production of inflammatory cytokines. The naïve group showed high levels of lung viral titers at both 3 and 6 days after infection (Fig 2D), resulting in the production of high levels of inflammatory cytokines (Fig 3) probably due to infiltrating innate and adaptive immune cells in the lungs. The M2e5x VLP vaccine group showed better control of lung viral titers by approximately 100 folds, which is resulting in lessening the innate immune cellular infiltrates and reduction in the levels of inflammatory cytokines (IFN-γ, TNF-α). Therefore, better control of viral replication in the
lungs by effective vaccination might have contributed to reducing the levels of inflammatory cytokines such as IFN-γ and TNF-α.

It may take time to induce antigen specific effector T cells (TNF-α+ and IFN-γ+ CD4 T cells) during viral infection of naïve mice even with high viral loads (Fig 6). The M2e5x VLP group showed a low level of vaccine-induced pre-existing antigen-specific TNF-α+ and IFN-γ+ CD4 T cells resident in the lung tissues and BAL before infection, which can secrete cytokines upon stimulation and rapidly expand during challenge infection (Fig 6). The presence of resident memory T cells in immune mice appears to attenuate inflammatory responses during influenza virus infection. Newly activated T cells are known to traffic to the lung parenchymal tissues from the draining lymph nodes [38]. IFN-γ or perforin expressing CD4 T cells were shown to enhance lung viral clearance and recovery [39, 40]. Expanded T cells in the M2e5x VLP group could have contributed to a better control of lung viral loads and a faster recovery from weight loss during a later stage of infection in addition to M2e antibodies, compared to the naïve mouse infection group (Fig 7). Better control of influenza virus loads will result in lowering the viral antigens available for activating antigen-specific T cells, which may also contribute to lowering the levels of inflammatory cytokines. The roles of CD4 and CD8 T cells were found to have similar effects on attenuating weight loss as evidenced by T cell depletion experiments. In contrast to the induction of CD4+ T cells producing cytokines upon stimulation with M2e peptides, mucosal vaccination with M2e5x VLPs induced low levels of M2e-specific cytokine producing CD8+ T cells, similar to those as detected in naïve mice after infection (data not shown). High viral loads in naïve mice led to the induction of CD8 T cells by day 7 after infection. Nonetheless, T cell immunity alone which was induced during viral replication in an unimmunized condition was not sufficient to control viral loads and unable to prevent severe weight loss in the absence of M2e antibodies as observed in naïve mice after infection. Depletion of CD8 T cells has higher impact of increasing lung viral loads than CD4 T cell depletion in the M2e5x VLP vaccinated group, suggesting the important role of CD8 T cell immunity. It is possible that cytotoxic CD8 T cells secreting granzyme B are likely contributing to further reducing lung viral loads. These results provide evidence that both M2e humoral and cellular immunity play a critical role in conferring protection after intranasal vaccination of mice with M2e5x VLP.

Supporting information

S1 Fig. Efficacy of T cell depletion. Groups of mice (n = 3, BALB/c mice) were treated with CD4 T cell depleting antibody (200 μg in 200 μl, Clone GK1.5), IgG isotype control (Clone LTF-2, rat IgG2b), or buffer (PBS) two times (days 0 and 2). At day 7, the T cell levels were determined in bloods by flow cytometry.

(PDF)

Author Contributions

Conceptualization: Young-Tae Lee.
Data curation: Young-Tae Lee, Ki-Hye Kim.
Formal analysis: Young-Tae Lee, Eun-Ju Ko, Youri Lee, Min-Chul Kim, Yu-Na Lee.
Funding acquisition: Sang-Moo Kang.
Investigation: Young-Tae Lee.
Project administration: Sang-Moo Kang.
Resources: Min-Chul Kim.
Supervision: Sang-Moo Kang.
Validation: Sang-Moo Kang.
Writing – review & editing: Sang-Moo Kang.

References
1. Osterholm MT. Preparing for the next pandemic. The New England journal of medicine. 2005; 352 (18):1839–42. Epub 2005/05/06. https://doi.org/10.1056/NEJMep058068 PMID: 15872196.
2. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr. 2010:RRN1153. Epub 2010/03/31. https://doi.org/10.1371/currents.RRN1153 PMID: 20352125.
3. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945–52. Epub 2009/09/12. https://doi.org/10.1056/NEJMoa0906453 PMID: 19745214.
4. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009; 459(7250):1122–5. Epub 2009/06/12. https://doi.org/10.1038/nature08182 PMID: 19516283.
5. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5(10):1157–63. https://doi.org/10.1038/13484 PMID: 10502819.
6. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 2005; 7(2):171–7. https://doi.org/10.1016/j.micinf.2004.10.006 PMID: 15777646.
7. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007; 13(3):426–35. Epub 2007/06/08. https://doi.org/10.3201/eid1303.061125 PMID: 17552096.
8. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004; 22(23–24):2993–3003. https://doi.org/10.1016/j.vaccine.2004.02.021 PMID: 15297047.
9. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008; 26(27–28):3395–403. Epub 2008/05/31. https://doi.org/10.1016/j.vaccine.2008.04.052 PMID: 18511159.
10. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine. 2009; 27(9):1440–7. Epub 2009/01/17. https://doi.org/10.1016/j.vaccine.2008.12.034 PMID: 19146898.
11. Wu F, Yuan XY, Li J, Chen YH. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine. 2009; 27(32):4320–4. Epub 2009/05/05. https://doi.org/10.1016/j.vaccine.2009.04.075 PMID: 19410621.
12. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology. 2005; 337(1):149–61. https://doi.org/10.1016/j.virol.2005.04.004 PMID: 15914228.
13. Heinen PP, Rijsewijk FA, de Boer-Luitje EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83(Pt 8):1851–9. https://doi.org/10.1099/0022-1317-83-8-1851 PMID: 12124449.
14. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004; 103(1–2):173–6. https://doi.org/10.1016/j.virusres.2004.02.030 PMID: 15163506.
15. Kim MC, Song JM, O E, Kwon YM, Lee YJ, Comps RW, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21(2):485–92. Epub 2012/12/19. https://doi.org/10.1038/mt.2012.246 PMID: 23247101.
16. Wang L, Wang YC, Feng H, Ahmed T, Companys RW, Wang BZ. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterotypic immune protection in mice. BioMed research international. 2013; 2013:686549. Epub 2013/08/29. https://doi.org/10.1155/2013/686549 PMID: 23984396.

17. Pei S, Xiong N, Zhang Y, Chen S. Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus. Biotechnol Lett. 2009; 31(12):1851–6. Epub 2009/08/20. https://doi.org/10.1007/s10529-009-0102-6 PMID: 19690809.

18. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol. 2010; 155(4):535–44. https://doi.org/10.1007/s00705-010-0621-4 PMID: 20195654.

19. Tamura S, Aina S, Suzuki T, Kurata T, Hasegawa H. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine? Jpn J Infect Dis. 2016; 69(3):165–79. https://doi.org/10.7883/yoken.JJID.2015.560 PMID: 27212584.

20. Song JM, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using micronized. Antiviral Res. 2010; 88(2):244–7. Epub 2010/09/21. https://doi.org/10.1016/j.antiviral.2010.09.001 PMID: 20851715.

21. Brito LA, Singh M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. 2011; 100(1):34–7. https://doi.org/10.1002/jps.22267 PMID: 20575063.

22. Lee YT, Ko EJ, Lee YN, Biaz N, Liu Y, et al. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza. Journal of virology. 2016; 90(15):6746–58. Epub 2016/05/20. https://doi.org/10.1128/JVI.00605-16 PMID: 27194758.

23. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene. 1938; 21:493–7.

24. Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol. 2007; 81(6):2736–44. https://doi.org/10.1128/JVI.00605-06 PMID: 17182684.

25. Kash JC, Basler CF, Garcia-Sastre A, Carter V, Billharz R, Swayne DE, et al. Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol. 2004; 78(17):9499–511. https://doi.org/10.1128/JVI.78.17.9499-9511.2004 PMID: 15306742.

26. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 2005; 438(7066):364–8. Epub 2005/11/18. https://doi.org/10.1038/nature04267 PMID: 16293212.

27. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, House K, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One. 2010; 5(10):e13162. https://doi.org/10.1371/journal.pone.0013162 PMID: 20976273.

28. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol. 2001; 75(11):5141–50. https://doi.org/10.1128/JVI.75.11.5141-5150.2001 PMID: 11333895.

29. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172(9):5598–605. PMID: 15100303.

30. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, et al. Protection against H1, H5, H6 and H9 influenza infection with liposomal matrix 2 epitope vaccines. Vaccine. 2006; 24(24):5158–68. https://doi.org/10.1016/j.vaccine.2006.04.008 PMID: 16713037.

31. Eliaison DG, Bakkouri KE, Schon K, Ramme A, Festjens E, Lowenadler B, et al. CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9):1243–52. https://doi.org/10.1016/j.vaccine.2007.12.027 PMID: 18243429.

32. Tissot AC, Renhofa R, Schmitz N, Cieliens I, Meijerink E, Ose V, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One. 2010; 5(3):e9809. https://doi.org/10.1371/journal.pone.0009809 PMID: 20352110.

33. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birckett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptor s and alveolar macrophages mediate protection. Journal of immunology. 2011; 186(2):1022–31. Epub 2010/12/21. https://doi.org/10.4049/jimmunol.0902147 PMID: 21169548.

34. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for
vaccine design. Eur J Immunol. 2008; 38(1):114–26. Epub 2007/12/18. https://doi.org/10.1002/eji.200636959 PMID: 18081037.

35. Lee YN, Kim MC, Lee YT, Hwang HS, Cho MK, Lee JS, et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine. 2014; 32(35):4578–85. Epub 2014/06/22. https://doi.org/10.1016/j.vaccine.2014.06.040 PMID: 24951867.

36. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016; 13(1):3–10. https://doi.org/10.1038/cmi.2015.74 PMID: 26189369.

37. Yokota S, Imagawa T, Miyamae T, Ito S, Nakajima S, Nezu A, et al. Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. Pediatr Int. 2000; 42(2):197–203. PMID: 10804742.

38. Suarez-Ramirez JE, Wu T, Lee YT, Aguila CC, Bouchard KR, Cauley LS. Division of labor between subsets of lymph node dendritic cells determines the specificity of the CD8(+) T-cell recall response to influenza infection. Eur J Immunol. 2011; 41(9):2632–41. https://doi.org/10.1002/eji.201141546 PMID: 21660939.

39. Baumgarth N, Kelso A. In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J Virol. 1996; 70(7):4411–8. PMID: 8676464.

40. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012; 86(12):6792–803. https://doi.org/10.1128/JVI.07172-11 PMID: 22491469.

41. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem. 2008; 283(17):11382–7. Epub 2008/02/07. https://doi.org/10.1074/jbc.M800650200 PMID: 18252707.